Several compounds that have been shown to combat SOD1-induced toxicity in transgenic mutant SOD1 mice are already underway in clinical trials for SOD1-linked ALS (ClinicalTrials.gov ID NCT04856982, NCT04082832), which we posit could represent potential means of combating disSOD1 pathology in Parkinson disease. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.